Amgen Completes Mustafa Nevzat Pharmaceuticals Acquisition

Thousand Oaks-based biopharmaceuticals firm Amgen said Tuesday afternoon that it has completed its acquisition of Turkish biopharma Mustafa Nevzat Pharmaceuticals. The acquisition, which had originally been announced on April 25th, was worth $700M in cash. Amgen said the buy will "significantly expand" its presence in Turkey and the surrounding region.